CPHI Milan 2024
October 8 - 10, 2024 | Milan, Italy
We are pleased to announce that we will attend CPHI at Milan. This event gathers thousands of industry leaders under one roof and brings endless opportunities to learn, innovate, and develop meaningful connections.
Connect with our experts and discover how we can design tailor-made solutions to achieve your business goals at every step, from transaction advisory services to market access, pricing, and reimbursement strategies.
Want to connect at CPHI? Contact us to set up a meeting.
Meet Our Delegates
Andrea Mantovani
Partner,
Market Access and Pricing
Nerea Blanqué-Catalina
Partner,
Market Access and Pricing
Ilda Theka
Engagement Manager,
Market Access and Pricing
Shaneze Chebbah
Principal,
Transaction Advisory Services
Christian Hughes
Senior Manager,
Transaction Advisory Services
Sofia Puzzi
Manager,
Transaction Advisory Services
Camille Abdelaziz
Manager,
Transaction Advisory Services
Andrea Rampolla
Associate,
Transaction Advisory Services
Read Our Latest Publications
White Papers and Reports
Download this white paper to learn about aspects of ATMPs development and commercialization challenges in access, future innovative solutions for ATMPs access, and patient views on ATMPs.
This in-depth report investigates the current trends in the fast-growing global medtech outsourcing industry, with an emphasis on Western Europe countries. What drove success and what does the future hold for this dynamic market?
Case Studies
A US biopharma company needed to validate the patient journeys and US reimbursement pathways for their two alpha-emitting radioligand therapies in two solid tumor indications. They also sought to understand the suitable price points for each asset.
A medtech company sought to develop a breakthrough in-vitro diagnostic (IVD) solution aimed at improving cardiac disease diagnosis. The client needed to create an early go-to-market strategy for the novel IVD solution to prepare for product development and launch in key European countries and the US.
A Swedish pharma company saw a market opportunity to expand access to its proprietary product outside of the Nordics and sought support developing strategic licensing deals.
A multinational pharma was evaluating a treatment for myasthenia gravis (MG). The client’s goal was to launch in multiple markets and sought support to incorporate early payer advice on clinical trial design, identify evidence gaps, and provide insights on the overall development program for the asset.
Discover How We Support Our Clients
Subscribe to our newsletter for the latest news, events, and thought leadership